Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens

Ovidiu Marina, Ursula Hainz, Melinda A. Biernacki, Wandi Zhang, Ann Cai, Jonathan S. Duke-Cohan, Fenglong Liu, Vladimir Brusic, Donna Neuberg, Jeffery L. Kutok, Edwin P. Alyea, Christine M. Canning, Robert J. Soiffer, Jerome Ritz, Catherine J. Wu

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Patients with chronic lymphocytic leukemia (CLL) who relapse after allogeneic transplant may achieve durable remission following donor lymphocyte infusion (DLI), showing the potency of donor-derived immunity in eradicating tumors. We sought to elucidate the antigenic basis of the effective graft-versus-leukemia (GvL) responses associated with DLI for the treatment of CLL by analyzing the specificity of plasma antibody responses developing in two DLI-treated patients who achieved long-term remission without graft-versus-host disease. By probing high-density protein microarrays with patient plasma, we discovered 35 predominantly intracellular antigens that elicited high-titer antibody reactivity greater in post-DLI than in pre-DLI plasma. Three antigens - C6orf130, MDS032, and ZFYVE19 - were identified by both patients. Along with additional candidate antigens DAPK3, SERBP1, and OGFOD1, these proteins showed higher transcript and protein expression in B cells and CLL cells compared with normal peripheral blood mononuclear cells. DAPK3 and the shared antigens do not represent minor histocompatibility antigens, as their sequences are identical in both donor and tumor. Although ZFYVE19, DAPK3, and OGFOD1 elicited minimal antibody reactivity in 12 normal subjects and 12 chemotherapy-treated CLL patients, 5 of 12 CLL patients with clinical GvL responses were serologically reactive to these antigens. Moreover, antibody reactivity against these antigens was temporally correlated with clinical disease regression. These B-cell antigens represent promising biomarkers of effective anti-CLL immunity.

Original languageEnglish
Pages (from-to)1344-1355
Number of pages12
JournalCancer Research
Volume70
Issue number4
DOIs
Publication statusPublished - Feb 15 2010
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Tumor Biomarkers
Immunity
B-Lymphocytes
Tissue Donors
Antigens
Lymphocytes
Transplants
Antibodies
Leukemia
Minor Histocompatibility Antigens
Protein Array Analysis
Graft vs Host Disease
Antibody Formation
Blood Cells
Neoplasms
Proteins
Biomarkers
Recurrence
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Marina, O., Hainz, U., Biernacki, M. A., Zhang, W., Cai, A., Duke-Cohan, J. S., ... Wu, C. J. (2010). Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens. Cancer Research, 70(4), 1344-1355. https://doi.org/10.1158/0008-5472.CAN-09-3143

Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens. / Marina, Ovidiu; Hainz, Ursula; Biernacki, Melinda A.; Zhang, Wandi; Cai, Ann; Duke-Cohan, Jonathan S.; Liu, Fenglong; Brusic, Vladimir; Neuberg, Donna; Kutok, Jeffery L.; Alyea, Edwin P.; Canning, Christine M.; Soiffer, Robert J.; Ritz, Jerome; Wu, Catherine J.

In: Cancer Research, Vol. 70, No. 4, 15.02.2010, p. 1344-1355.

Research output: Contribution to journalArticle

Marina, O, Hainz, U, Biernacki, MA, Zhang, W, Cai, A, Duke-Cohan, JS, Liu, F, Brusic, V, Neuberg, D, Kutok, JL, Alyea, EP, Canning, CM, Soiffer, RJ, Ritz, J & Wu, CJ 2010, 'Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens', Cancer Research, vol. 70, no. 4, pp. 1344-1355. https://doi.org/10.1158/0008-5472.CAN-09-3143
Marina, Ovidiu ; Hainz, Ursula ; Biernacki, Melinda A. ; Zhang, Wandi ; Cai, Ann ; Duke-Cohan, Jonathan S. ; Liu, Fenglong ; Brusic, Vladimir ; Neuberg, Donna ; Kutok, Jeffery L. ; Alyea, Edwin P. ; Canning, Christine M. ; Soiffer, Robert J. ; Ritz, Jerome ; Wu, Catherine J. / Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens. In: Cancer Research. 2010 ; Vol. 70, No. 4. pp. 1344-1355.
@article{f6800841394b4aee9c19f3eff0d31bb4,
title = "Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens",
abstract = "Patients with chronic lymphocytic leukemia (CLL) who relapse after allogeneic transplant may achieve durable remission following donor lymphocyte infusion (DLI), showing the potency of donor-derived immunity in eradicating tumors. We sought to elucidate the antigenic basis of the effective graft-versus-leukemia (GvL) responses associated with DLI for the treatment of CLL by analyzing the specificity of plasma antibody responses developing in two DLI-treated patients who achieved long-term remission without graft-versus-host disease. By probing high-density protein microarrays with patient plasma, we discovered 35 predominantly intracellular antigens that elicited high-titer antibody reactivity greater in post-DLI than in pre-DLI plasma. Three antigens - C6orf130, MDS032, and ZFYVE19 - were identified by both patients. Along with additional candidate antigens DAPK3, SERBP1, and OGFOD1, these proteins showed higher transcript and protein expression in B cells and CLL cells compared with normal peripheral blood mononuclear cells. DAPK3 and the shared antigens do not represent minor histocompatibility antigens, as their sequences are identical in both donor and tumor. Although ZFYVE19, DAPK3, and OGFOD1 elicited minimal antibody reactivity in 12 normal subjects and 12 chemotherapy-treated CLL patients, 5 of 12 CLL patients with clinical GvL responses were serologically reactive to these antigens. Moreover, antibody reactivity against these antigens was temporally correlated with clinical disease regression. These B-cell antigens represent promising biomarkers of effective anti-CLL immunity.",
author = "Ovidiu Marina and Ursula Hainz and Biernacki, {Melinda A.} and Wandi Zhang and Ann Cai and Duke-Cohan, {Jonathan S.} and Fenglong Liu and Vladimir Brusic and Donna Neuberg and Kutok, {Jeffery L.} and Alyea, {Edwin P.} and Canning, {Christine M.} and Soiffer, {Robert J.} and Jerome Ritz and Wu, {Catherine J.}",
year = "2010",
month = "2",
day = "15",
doi = "10.1158/0008-5472.CAN-09-3143",
language = "English",
volume = "70",
pages = "1344--1355",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens

AU - Marina, Ovidiu

AU - Hainz, Ursula

AU - Biernacki, Melinda A.

AU - Zhang, Wandi

AU - Cai, Ann

AU - Duke-Cohan, Jonathan S.

AU - Liu, Fenglong

AU - Brusic, Vladimir

AU - Neuberg, Donna

AU - Kutok, Jeffery L.

AU - Alyea, Edwin P.

AU - Canning, Christine M.

AU - Soiffer, Robert J.

AU - Ritz, Jerome

AU - Wu, Catherine J.

PY - 2010/2/15

Y1 - 2010/2/15

N2 - Patients with chronic lymphocytic leukemia (CLL) who relapse after allogeneic transplant may achieve durable remission following donor lymphocyte infusion (DLI), showing the potency of donor-derived immunity in eradicating tumors. We sought to elucidate the antigenic basis of the effective graft-versus-leukemia (GvL) responses associated with DLI for the treatment of CLL by analyzing the specificity of plasma antibody responses developing in two DLI-treated patients who achieved long-term remission without graft-versus-host disease. By probing high-density protein microarrays with patient plasma, we discovered 35 predominantly intracellular antigens that elicited high-titer antibody reactivity greater in post-DLI than in pre-DLI plasma. Three antigens - C6orf130, MDS032, and ZFYVE19 - were identified by both patients. Along with additional candidate antigens DAPK3, SERBP1, and OGFOD1, these proteins showed higher transcript and protein expression in B cells and CLL cells compared with normal peripheral blood mononuclear cells. DAPK3 and the shared antigens do not represent minor histocompatibility antigens, as their sequences are identical in both donor and tumor. Although ZFYVE19, DAPK3, and OGFOD1 elicited minimal antibody reactivity in 12 normal subjects and 12 chemotherapy-treated CLL patients, 5 of 12 CLL patients with clinical GvL responses were serologically reactive to these antigens. Moreover, antibody reactivity against these antigens was temporally correlated with clinical disease regression. These B-cell antigens represent promising biomarkers of effective anti-CLL immunity.

AB - Patients with chronic lymphocytic leukemia (CLL) who relapse after allogeneic transplant may achieve durable remission following donor lymphocyte infusion (DLI), showing the potency of donor-derived immunity in eradicating tumors. We sought to elucidate the antigenic basis of the effective graft-versus-leukemia (GvL) responses associated with DLI for the treatment of CLL by analyzing the specificity of plasma antibody responses developing in two DLI-treated patients who achieved long-term remission without graft-versus-host disease. By probing high-density protein microarrays with patient plasma, we discovered 35 predominantly intracellular antigens that elicited high-titer antibody reactivity greater in post-DLI than in pre-DLI plasma. Three antigens - C6orf130, MDS032, and ZFYVE19 - were identified by both patients. Along with additional candidate antigens DAPK3, SERBP1, and OGFOD1, these proteins showed higher transcript and protein expression in B cells and CLL cells compared with normal peripheral blood mononuclear cells. DAPK3 and the shared antigens do not represent minor histocompatibility antigens, as their sequences are identical in both donor and tumor. Although ZFYVE19, DAPK3, and OGFOD1 elicited minimal antibody reactivity in 12 normal subjects and 12 chemotherapy-treated CLL patients, 5 of 12 CLL patients with clinical GvL responses were serologically reactive to these antigens. Moreover, antibody reactivity against these antigens was temporally correlated with clinical disease regression. These B-cell antigens represent promising biomarkers of effective anti-CLL immunity.

UR - http://www.scopus.com/inward/record.url?scp=76749123948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76749123948&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-09-3143

DO - 10.1158/0008-5472.CAN-09-3143

M3 - Article

C2 - 20124481

AN - SCOPUS:76749123948

VL - 70

SP - 1344

EP - 1355

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 4

ER -